TIGIT inhibitors have long been in a difficult race toward the finish line on the non-small cell lung cancer (NSCLC) track. At the European Society for Medical Oncology (ESMO) Congress 2024, and iTeos finally provided the first data reveal of their TIGIT inhibitor, belrestotug, in combination with Jemperli (dostarlimab) in the first-line, PD-L1-high setting of NSCLC. Dr.
David R. Spigel presented the interim analysis on the Phase II, open-label, GALAXIES Lung-201 trial at an overall median follow-up of 7.3 months.
At all three dose levels of belrestotug (100, 400, and 1000mg), belrestotug + dostarlimab demonstrated an almost doubled confirmed overall response rate (ORR) over dostarlimab monotherapy, with over 90% decrease in circulating tumour DNA (ctDNA) in higher dose levels. Although the data presented shed a positive light on the combination’s potential, the interim analysis did not provide any insights on key secondary survival and durability endpoints, and ultimately, on how the combination compares with the well-established stand of care, MSD’s Keytruda (pembrolizumab), in the comparator arm. The current analysis only included 124 patients at the data cut-off, which is less than half of the 300 enrolment pool, leading to a minimal data size (about 30 patients) in each intervention arm.
Like its fellow TIGIT competitors, the published data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm. Belrestotug 400mg was sel.